about
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesisEvidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic PathwayFitness trade-offs restrict the evolution of resistance to amphotericin BEndothelial Thermotolerance Impairs Nanoparticle Transport in Tumors.Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates.Calcineurin determines toxic versus beneficial responses to α-synuclein.HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.Susan Lindquist (1949-2016).The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicansBiomimetic kinetic resolution: highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products.High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.The stress response: implications for the clinical development of hsp90 inhibitors.Nontoxic antimicrobials that evade drug resistance.Using the heat-shock response to discover anticancer compounds that target protein homeostasis.Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desertHsp90: an emerging target for breast cancer therapy.Altered Hsp90 function in cancer: a unique therapeutic opportunity.Geopyxins A-E, ent-kaurane diterpenoids from endolichenic fungal strains Geopyxis aff. majalis and Geopyxis sp. AZ0066: structure-activity relationships of geopyxins and their analogues.Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indolesLoss of tumor suppressor NF1 activates HSF1 to promote carcinogenesisInhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.HSP90: a rising star on the horizon of anticancer targets.Heat shock protein 90: a unique chemotherapeutic target.Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious diseaseExpression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegansHSP90 as a platform for the assembly of more effective cancer chemotherapy.Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state.HSP90 Shapes the Consequences of Human Genetic Variation.Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.A rhizosphere fungus enhances Arabidopsis thermotolerance through production of an HSP90 inhibitor.Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity.The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways.A new dihydroxanthenone from a plant-associated strain of the fungus Chaetomium globosum demonstrates anticancer activity.Cytotoxic constituents of Aspergillus terreus from the rhizosphere of Opuntia versicolor of the Sonoran Desert.2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera.Isolation, optimization of production and structure-activity relationship studies of monocillin I, the cytotoxic constituent of Paraphaeosphaeria quadriseptata.Synthesis of Aza-Rocaglates via ESIPT-Mediated (3+2) Photocycloaddition
P50
Q24655006-ED6E13EF-D9CC-48A8-AD15-9450344ABE3DQ24809567-422F47A6-D5A5-49F4-917C-1ECD4CA47F96Q28534687-FB18672C-D01A-4ADF-82A4-B8CB93F13E77Q30376502-319A9418-BEA6-4A76-854D-E3309D3BE973Q31018268-C0D42752-9FB8-4CFB-B5F8-A947247672ECQ33976044-69993E81-8D31-4EC2-8407-23EA9A6A2E97Q34120215-FF2F54DA-D867-44A1-8F34-9EFDCFD47594Q34292197-CD20A029-4BEF-4DF8-A532-D0F5D09EE736Q34545815-9EB772F6-35A5-4405-BB2A-32D8A43F856AQ34599918-526A7293-EB31-476B-AA42-737B2D740358Q34793260-041DA4E0-8203-489E-ADBE-E6198812E619Q34942381-F23C20A9-88C5-43D4-92AF-BD8B13F1BD98Q35005931-C3301396-035A-4792-91B4-FDC668B8C212Q35546764-EEF00ADF-B786-447F-96F1-9B473E7CF450Q35551875-BB2D5ADA-4F96-423B-846E-59941AD587B6Q35756422-D167F4D8-A112-4238-8812-0EC0DCC4EECDQ35794082-34A3AC07-CF6C-4C96-B2C3-117E0F382F43Q35809597-953B47BC-0A0F-47CA-9CC4-0AE91D67FB19Q35843175-243FA4E5-6198-403E-9F0C-95240658ECECQ35858031-F98AD1D4-87C0-442A-9B5A-BC079BFF1786Q35986942-20D9D5F4-926A-4A97-8AD4-E21C364FEB3BQ36068254-DDD74821-3211-4113-BFB4-ECA82E605DACQ36290277-913FA574-B074-4ADB-80F3-C5A6B1456742Q36368265-FF48B2F7-C6C3-45F8-812E-84F013D8E086Q36429542-1DF38E6E-F1BD-4F91-9F6F-E07A9AE71D05Q36557301-B88E9512-E34D-40C1-B86D-5274590C32EDQ37115266-467D1EA6-0E75-477B-B820-3ACD96E16123Q37490567-0EC62F78-5FBA-4F0B-B74A-51D043EB6397Q37973573-59437C13-E5C7-4AA3-B540-835281DEBC21Q38361655-4A823681-F84A-4072-A855-E4662DDC0866Q38953212-083276A9-D002-4901-A5BD-D6943C1C83C1Q39125133-6F5F9EBD-3448-4C68-98B5-8E77A6620223Q39236769-42289E98-4D38-402C-8E90-0CC9A2E56084Q39326660-36FB6F79-3068-4A59-85F7-55FE30479048Q39538145-96743753-EAAD-4280-8A29-1270F0F94E40Q39592546-D6D655F8-97C9-4090-8B17-F8F882CD7007Q39592555-37495529-4A71-4B9A-B545-D0B4CC18DD7BQ39908922-654C5A79-3128-4AE2-8C1A-9A589C05DA62Q40498244-AE487E71-A3DE-42B9-A13A-86C8BF5F0AC4Q41161750-AEE91252-B517-4B5F-A180-B7DCC123FD0A
P50
description
researcher ORCID ID = 0000-0001-6445-5766
@en
wetenschapper
@nl
name
Luke Whitesell
@ast
Luke Whitesell
@en
Luke Whitesell
@es
Luke Whitesell
@nl
type
label
Luke Whitesell
@ast
Luke Whitesell
@en
Luke Whitesell
@es
Luke Whitesell
@nl
prefLabel
Luke Whitesell
@ast
Luke Whitesell
@en
Luke Whitesell
@es
Luke Whitesell
@nl
P21
P31
P496
0000-0001-6445-5766